Skip to main content
PRQR
NASDAQ Life Sciences

ProQR Reports Wider Q1 Loss and Significant Revenue Miss; Pipeline Advances with Extended Cash Runway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$1.59
Mkt Cap
$169.631M
52W Low
$1.33
52W High
$3.1
52W Position info
20% above low
Off High info
49% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

PRQR sits 20% above its 52-week low of $1.33.

Summary

ProQR Therapeutics announced Q1 2026 results with a wider net loss and revenue significantly below expectations, but highlighted reduced cash burn, an extended cash runway into mid-2027, and ongoing pipeline advancements.


Key Events · Earnings and Guidance · PRQR

  • Q1 2026 Financial Performance

    The company reported a net loss of €13.4 million for Q1 2026, an increase from €10.1 million in Q1 2025. Revenue for the quarter was €2.03 million, significantly missing analyst estimates of €5.25 million.

  • Reduced Cash Burn and Extended Runway

    Net cash used in operating activities decreased to €11.1 million in Q1 2026 from €15.8 million in Q1 2025. ProQR ended the quarter with €81.1 million in cash and cash equivalents, providing a runway into mid-2027.

  • Pipeline Advancement and Upcoming Milestones

    AX-0810 target engagement data in healthy volunteers is on track for Q2 2026, with biliary atresia selected as the initial Phase 2 indication for an investigator-initiated trial in China (data targeted H1 2027). Other programs (AX-0811, AX-0422, AX-2911) are advancing towards CTA filings and initial clinical data in 2026-2027.

  • Axiomer Platform Development

    ProQR continues to enhance its Axiomer™ RNA editing platform through AI-enabled discovery, including a strategic partnership with Ginkgo Bioworks and the formation of an AI Advisory Board.


Analysis · PRQR · Life Sciences

ProQR Therapeutics reported a significant increase in net loss and revenue that substantially missed analyst estimates for Q1 2026. This financial underperformance is a strong negative signal. However, the company also demonstrated a reduced cash burn and confirmed a cash runway into mid-2027, which is critical for a clinical-stage biotech. Additionally, ProQR provided updates on its pipeline, including upcoming clinical data for AX-0810 and the advancement of several other programs, offering future catalysts.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRQR was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $169.6M. The 52-week trading range was $1.33 to $3.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRQR - Latest Insights

PRQR
Sep 09, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $2.05
Real-time Price: $1.40 info
Change: -$0.6525 (-32%) info
Market Cap: $197.217M info
PRQR
Aug 13, 2026, 7:11 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.91
Real-time Price: $1.40 info
Change: -$0.5125 (-27%) info
Market Cap: $197.217M info
PRQR
Aug 13, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.85
Real-time Price: $1.40 info
Change: -$0.4533 (-24%) info
Market Cap: $197.217M info
PRQR
Aug 13, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.91
Real-time Price: $1.40 info
Change: -$0.5125 (-27%) info
Market Cap: $197.217M info
PRQR
Aug 03, 2026, 4:01 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.77
Real-time Price: $1.40 info
Change: -$0.3725 (-21%) info
Market Cap: $197.217M info